Trial Profile
A Double-Blind, Placebo-Controlled, Randomized, Multicenter Phase III Study Evaluating the Efficacy and Safety of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction and Gastric Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Dec 2022
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Capecitabine; Cisplatin; Fluoropyrimidine derivatives; Fluorouracil; Trastuzumab
- Indications Adenocarcinoma; Gastric cancer; HER2 positive breast cancer; Oesophageal cancer
- Focus Registrational; Therapeutic Use
- Acronyms JACOB
- Sponsors Chugai Pharmaceutical; Roche
- 22 Nov 2022 Results of post-hoc analysis published in the Clinical Cancer Research.
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress
- 21 Nov 2020 This study has been discontinued in Italy, according to European Clinical Trials Database record.